Related Experiment Video
Updated: Aug 26, 2026

Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells
Published on: June 7, 2019
Frequent alterations of Ras signaling pathway genes in sporadic malignant melanomas
Julia Reifenberger1, Christiane B Knobbe, Astrid A Sterzinger
1Department of Dermatology, Heinrich-Heine-University, Düsseldorf, Germany. reifenbergerj@med.uni-duesseldorf.de
Abstract:
Ras signaling is important for the intracellular transduction of mitogenic stimuli from activated growth factor receptors. We have investigated 37 sporadic malignant melanomas (15 primary cutaneous melanomas and 22 melanoma metastases) and 6 melanoma cell lines for mutations in the 3 Ras genes NRAS, KRAS and HRAS. All tumors and cell lines were additionally analyzed for mutation and expression of BRAF, which encodes a Ras-regulated serine/threonine kinase with oncogenic properties, as well as for expression of RASSF1A, which encodes a Ras-binding protein with tumor suppressor properties. Mutational analyses identified somatic NRAS mutations in 2 primary melanomas, 4 melanoma metastases and 2 cell lines. One melanoma metastasis showed a somatic KRAS mutation whereas HRAS mutations were not detected. Eight primary melanomas, 6 melanoma metastases and 4 melanoma cell lines carried BRAF mutations affecting the known hot-spot codon 599. None of the tumors or cell lines with BRAF mutation demonstrated NRAS or KRAS mutations. Real-time reverse transcription-PCR showed that 8 melanomas (3 primary tumors, 5 melanoma metastases) had reduced RASSF1A transcript levels of < or =50% relative to benign melanocytic nevi and normal skin. Three melanoma cell lines lacked detectable RASSF1A transcripts. The RASSF1A gene promoter was hypermethylated in these 3 cell lines as well as in 6 of 8 melanomas with reduced RASSF1A mRNA levels. Treatment of the cell lines with 5-aza-2'-deoxycytidine and trichostatin A resulted in demethylation of the RASSF1A promoter and re-expression of RASSF1A transcripts. Most tumors and all cell lines with RASSF1A promoter methylation additionally carried BRAF or NRAS mutations, suggesting a synergistic effect of these aberrations on melanoma growth. Taken together, 57% of the investigated melanomas and 100% of the melanoma cell lines carried mutations in either NRAS, KRAS or BRAF. In addition, 22% of the melanomas and 50% of the cell lines showed reduced RASSF1A transcript levels. Thus, alterations of Ras pathway genes are of paramount importance in the pathogenesis of sporadic melanomas.
Insights
Mutations in Ras pathway genes like NRAS, KRAS, and BRAF are frequent in sporadic melanomas. Aberrant expression of the tumor suppressor RASSF1A, often due to gene promoter methylation, also contributes to melanoma development.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Ras signaling pathways are crucial for transmitting mitogenic signals from growth factor receptors.
- Dysregulation of these pathways is implicated in various cancers, including melanoma.
Purpose of the Study:
- To investigate mutations in NRAS, KRAS, and HRAS genes in sporadic melanomas.
- To analyze BRAF mutations and RASSF1A expression and methylation in melanoma.
- To understand the interplay between Ras pathway gene alterations and melanoma pathogenesis.
Main Methods:
- Mutational analysis of NRAS, KRAS, HRAS, and BRAF genes in melanoma samples and cell lines.
- Real-time reverse transcription-PCR for RASSF1A transcript levels.
- Analysis of RASSF1A gene promoter methylation.
- Treatment with demethylating agents (5-aza-2'-deoxycytidine and trichostatin A).
Main Results:
- Somatic mutations were identified in NRAS (7/37 melanomas), KRAS (1/37 melanomas), and BRAF (14/37 melanomas).
- BRAF and NRAS/KRAS mutations were mutually exclusive.
- Reduced RASSF1A transcript levels were observed in 22% of melanomas and 50% of cell lines, often associated with promoter hypermethylation.
- Demethylation and re-expression of RASSF1A were achieved with specific treatments.
Conclusions:
- Alterations in Ras pathway genes (NRAS, KRAS, BRAF) are highly prevalent in sporadic melanomas, occurring in 57% of tumors and 100% of cell lines.
- RASSF1A silencing via promoter methylation is a significant event in melanoma, frequently co-occurring with BRAF or NRAS mutations.
- These genetic and epigenetic alterations collectively underscore the critical role of the Ras pathway in melanoma development.
Related Concept Videos
The Ras Gene
Ras is a superfamily...
MAPK Signaling Cascades
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Small GTPases - Ras and Rho
Three regulatory proteins control their activity:
Abnormal Proliferation

